pharma · Major Depressive Disorder (MDD), with or without Anxious Distress · Major Depressive Disorder (MDD) · SPTX
Seaport Therapeutics
Seaport Therapeutics is a pharma organization headquartered in Boston, USA. It trades on NYSE under ticker SPTX. Primary therapeutic focus areas include Major Depressive Disorder (MDD), with or without Anxious Distress,
Boston, USA HQ
68 Employees
Public company Type
SPTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Boston, USA
- Employees
- 68
- Programs
- 3
- Drugs
- 3
- Patents
- 1
SPT-300
Phase 2 · small molecule · Major Depressive Disorder (MDD)
SPT-300 for Major Depressive Disorder (MDD) is a Phase 2 program (small_molecule) at Seaport Therapeutics with 2 ClinicalTrials.gov record(s).
Internal code SPT-300-2024-203
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Seaport Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Major Depressive Disorder (MDD)
- Status
- active
- Trials
- 2